Overview
Public Biotech
Clinical-stage biotech developing ketamine and MDMA-based treatments for addiction, with focus on Alcohol Use Disorder. AWKN-001 ketamine therapy in Phase 3 for AUD showed 86% abstinence at 6 months.
Visit WebsiteLondon, UK
$25M
Market Cap
2019
Founded
0
Open Roles
Open Positions
No open positions at this time
Clinical Pipeline
No clinical trials on record